Screener
Rigel Pharmaceuticals RIGL Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001034842-26-000032
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Research and development | 11,676 | 8,436 |
| Selling, general and administrative | 30,651 | 27,715 |
| Total costs and expenses | 46,933 | 40,560 |
| Income from operations | 11,885 | 12,773 |
| Interest income | 1,205 | 591 |
| Interest expense | (1,433) | (1,853) |
| Income before income taxes | 11,657 | 11,511 |
| Provision for income taxes | 3,003 | 65 |
Item 1. Financial Statements
FAQ
- What is Rigel Pharmaceuticals's operating income?
- Rigel Pharmaceuticals (RIGL) reported operating income of $11.89M in Q1 2026.
- How has Rigel Pharmaceuticals's operating income changed year-over-year?
- Rigel Pharmaceuticals's operating income decreased by 7.0% year-over-year, from $12.77M to $11.89M.
- What is the long-term trend for Rigel Pharmaceuticals's operating income?
- Over 4 years (2021 to 2025), Rigel Pharmaceuticals's operating income has grown at a 78.0% compound annual growth rate (CAGR), from -$12.5M to $125.47M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Rigel Pharmaceuticals's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude